Artemether and Quinine are Safe and Effective in the Treatment of Severe Malaria in Nigerian Children

O.A. Osonuga1, A.D.A Adedapo2 and O.G. Ademowo2,3*

1Department of Physiology, Olabisi Onabanjo University. Ago Iwoye, Nigeria
2Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan. Ibadan, Nigeria
3Institute of Advanced Medical Research and Training, College of Medicine, University of Ibadan. Ibadan, Nigeria

Received: March 2018; Accepted: September, 2018

Abstract
Severe malaria is a medical emergency. Parenteral artesunate is recommended over quinine for severe malaria. Artemether, is an alternative to parenteral artesunate in certain settings. The study the efficacy and safety of quinine with artemether. An open randomized trial conducted at the pediatric ward of a specialist care center. Thirty-two patients with severe malaria were randomly assigned to receive either artemether, 3.2mg/kg start and 1.6 mg/kg body weight intramuscularly daily for 4 days or quinine, 10mg/kg body weight in 5% dextrose/saline intravenously 8 hourly till recovery from coma or able to take oral dose. Patients were followed up for 14 days. Mean fever clearance time for quinine was significantly lower when compared with artemether, (46.5 ± 20.5 versus 72.00 ± 27.7 hours; P=0.006). The malaria parasite clearance time was however significantly lower with artemether than with quinine (31.5 ± 14.5 versus 46.5 ± 6.00 hours; P=0.001). Adverse events, including tinnitus and insomnia in quinine group were generally mild. There was no adverse effect observed with artemether. Quinine and artemether were both effective and safe in the treatment of severe malaria in children. Artemether was better tolerated, cleared parasite faster with earlier and sustained recovery from anaemia, jaundice and coma.

Key Words: Quinine, Artemether, Severe malaria, Antimalarial activity, Children

INTRODUCTION
Malaria remains an endemic disease in up to 40% of the world population. The WHO reported an incidence of 212 million cases in 2015, 90% in Africa, 7% in South East Asia, and 2% in Eastern Mediterranean (WHO, 2016). Approximately 2% of clinical attacks of malaria in African children are severe. About 303 000 deaths occur in young children (under 5 years) with a child dying every 2 minutes (WHO, 2016). However, adults are relatively semi immune (Ademowo et al., 1995). Plasmodium falciparum causes the most severe form of malaria and is also the most deadly. If not treated promptly could result in severe malaria, which includes cerebral malaria and severe anaemia (Olu mese et al., 2002). Cerebral malaria can have a mortality rate of up to 25%, even with the best of treatment.

The rapidity by which malaria devastates children in Africa calls for urgent review of malaria therapy and management. Quinine, an antimalarial drug for severe malaria in children has complex dosing regimen, poor adherence and is poorly tolerated (Achan et al., 2011). There is need for reappraisal and search for effective and safer drugs for patients with severe malaria. It is on this basis that a comparative study of the efficacy of artemether and quinine in the treatment of severe malaria in children was designed. Artemether, a rapidly schizonticidal agent is combined with lumefantrine as a first line artemisinin-based combination therapy (ACT) for the treatment of uncomplicated P. falciparum malaria and administered intramuscularly is an alternative to parenteral artesunate for severe malaria (WHO, 2015). In Nigeria, malaria parasites were reported to be sensitive to quinine, hence reserved for initial treatment of severe and complicated falciparum malaria (Sowunn and Salako, 1992; Olum ese et al., 1999; Dondorp et al., 2010). However, quinine resistance has been reported (Adam et al., 2002; Pukrittayakamee et al., 2003). Alternatives to quinine are needed in view of the reported resistance, potential toxicity and intravenous route of administration, which may not be practical in rural areas (Karbwang et al., 1995). Parenteral artesunate has been advocated as the treatment of choice, in place quinine, for severe malaria globally (Dondorp et al., 2010). Artesunate is administered at a dose of 2.4mg/kg by slow intravenous injection over 5 minutes or IM, repeated at 12 and 24 hours, then once daily for up to 6 days if patient is unable to take orally; and mandatorily for 24 hours even if patient can take orally before 24 hours (Federal Ministry of Health, 2013). Intravenous administration and cumbersome method of preparation (Malaria Action Program for States, 2013) are also potential setback for parenteral artesunate.

This study was designed with the overall aim of determining the relative efficacy and safety of quinine and artemether in the treatment of severe malaria. The AQUAMAT study recommends intravenous artesunate over quinine in children less than 15 years of age (Dondorp et al., 2010).

*Author for Correspondence: +234-8023342856
E-mail: ogademowo@gmail.com
MATERIALS AND METHODS

Patients were recruited from the Overcomers Specialist Hospital, Ilisan and General Hospital Ikenne, Ogun State, Nigeria. Ethical approval for the study was obtained from the Olabisi Onabanjo University/Olabisi Onabanjo University Teaching Hospital joint ethical review committee. Inclusion criteria included children with either sex, age ranging from 1 to 12 years, Fever (temperature >37.5%) within the last 24 hours, microscopically proven malaria parasitaemia, presence of convulsion, hypoglycaemia and anaemia. Informed consent was obtained from the parents or guardians with the assurance that patients will be resident within catchments area of the study for follow-up. Exclusion criteria included presence of concomitant illness such as bronchopneumonia, typhoid, meningitis and urinary tract infection, history of blood transfusion in the last two months, history of previous allergy to quinine or artemether, and lack of informed consent. Withdrawal criteria included development of any concomitant illness during the study, withdrawal of informed consent by parent or guardian, unwillingness to continue in the study and failure to comply with protocol.

Patients who satisfied the criteria above were admitted for treatment in the ward. The children were randomly allocated into 2 treatment groups; for quinine and artemether respectively. On enrolment, a detailed history and clinical examination was carried out. The following were documented for each patient, body weight, body temperature, presence or absence of pallor, drowsiness, respiratory distress, convulsion, jaundice, coma, dehydration, urine retention, abnormal chest signs and liver or spleen enlargement. Before administration of drug, blood sample was collected for the following tests: thick and thin blood films for malaria parasite identification and quantification, random blood glucose, packed cell volume and full blood count. Urine was also collected for urinalysis, which was done using Combi 9 Clinitex for albumin, glucose and haemoglobinuria.

Patients in the quinine group received quinine (Evans) 10 mg/kg in 5% dextrose/saline infusion, which was administered to the patients through intravenous cannula for 4 hours. This served as the loading dose. Maintenance dose was given as 10 mg/kg dose, and then repeated 8 hourly. The quinine infusion was later changed to oral medication when patient’s clinical condition allowed for this. An oral dose of 10 mg/kg was then given 8 hourly. The duration of treatment was 7 days. The patients were monitored for toxic reactions such as vertigo, tinnitus, disturbed vision, haemolysis, convulsion, restlessness and syncope. Patients in the artemether group received 3.2 mg/kg artemether on day 0 and then 1.6 mg/kg daily for the next four days through deep intramuscular route. Each patient was monitored for adverse reactions, which were documented. The patients were only discharged after their clinical conditions became stable and good response to treatment attained. This happened usually after the third day. Treatment outcome of all patients in the 2 groups was assessed in terms of clinical and parasitological response. Parasite clearance time was defined as the time from drug administration until there was no patent peripheral parasitaemia for at least 48 hours. Fever clearance time was defined as the time from drug administration until the axillary temperature drops below 37.5°C and remained so for at least 72 hours. Symptoms clearance time was defined as the time between initiation of drug administration and the disappearance of all presenting symptoms of malaria.

Adverse effects were compared in the two groups. The intensity of adverse experience was classified as follows:

- **Mild** – An adverse experience that can be tolerated by the patient causing minimal discomfort without interfering with everyday activities.
- **Moderate** – An adverse experience that is sufficiently discomforting to interfere with normal everyday activities.
- **Severe** – An adverse experience that prevented normal daily activities, prolonged hospitalization or resulted in death.

Therapy was considered safe when adverse event was mild or moderate.

**Treatment success** if parasite count on day 3 was <25% of pre-treatment count, and there was no parasitaemia on days 7 and 14.

**Statistical Analysis:**

Data was analyzed using Epi-info version 6. Proportions were compared by calculating chi-square with Yates’s correction. Normally distributed data for example, weight and temperature were compared by student’s t-test. Kruskal – Wallis test was used to compare data not conforming to normal distribution e.g. parasite density. Values are given in the text and tables as mean ± standard deviation. P-values less than 0.05 were taken as statistically significant.

**RESULTS**

Thirty-four patients who met the inclusion criteria were enrolled into the study. Thirty-two patients with 16 in each group successfully completed the study. Their age ranged from 1 to 12 years (mean 7.0 ± 3.6) and weight ranged from 7.0 to 35.0 kg (mean 19.8 ± 8.2) (Table I).

The presenting symptoms in the patients were poor appetite, fever, vomiting, chill/rigor, drowsiness, dark urine, body aches, cough and convulsion. The presenting clinical features of the patients are shown on Table 1. There were no significant differences in the features between those in the quinine and artemether treatment groups.

The parasite density in the study group ranged from 71,500 to 140,024/µl of blood (mean 95,122.63 ±16,044). The quinine group had a range of 71,500 to 140,024/µl (mean 98,425/µl ±12,481) while the artemether group had a range of 72,500 to 140,024/µl (mean 100,820/µl ±17,520). Both groups were comparable, (P >0.05). Parasitaemia reduced progressively over time in the course of treatment. Parasite cleared in all patients by day 3 in both quinine and artemether groups except in one patient in the artemether group in whom parasitaemia only cleared by day 7 (Fig 1). The mean parasite clearance time was significantly reduced in artemether group (31.5 ± 14.5 hr) compared with quinine (46.5 ± 6.0 hr; P = 0.001). A total of 28 out of the 32 patients enrolled into the study had fever (temperature ≥37.5°C) at day 0, with 14 in each of the two groups. At day 3, seven of the patients in artemether group but only 1 of the patients in quinine group still had fever. By day 7, no fever was seen in quinine group while 2 of the patients in artemether group still had fever. However, by day 14, fever had cleared in all patients. The fever clearance time for quinine (46.5 ± 20.5 hours) was significantly reduced relative to artemether, which was 72.0 ± 27.7 hours (p-value =0.006) (Fig. 2).
Table 1:
Pattern of Clinical Presentation at Recruitment

<table>
<thead>
<tr>
<th>Clinical Presentation</th>
<th>Quinine</th>
<th>Artemether</th>
<th>Total</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>8.24 ± 3.44</td>
<td>6.00 ± 3.71</td>
<td>7.00 ± 3.65</td>
<td>0.64</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>20.78 ± 7.80</td>
<td>18.88 ± 8.72</td>
<td>19.83 ± 8.22</td>
<td>0.71</td>
</tr>
<tr>
<td>Fever</td>
<td>13 (48%)</td>
<td>14 (52%)</td>
<td>27 (100%)</td>
<td>0.71</td>
</tr>
<tr>
<td>Vomiting</td>
<td>14 (43.8%)</td>
<td>10 (31.2%)</td>
<td>24 (75%)</td>
<td>0.10</td>
</tr>
<tr>
<td>Poor appetite</td>
<td>15 (46.9%)</td>
<td>16 (50%)</td>
<td>31 (96.9%)</td>
<td>0.31</td>
</tr>
<tr>
<td>Chills/rigor</td>
<td>11 (34.4%)</td>
<td>9 (28.1%)</td>
<td>20 (62.5%)</td>
<td>0.46</td>
</tr>
<tr>
<td>Nausea</td>
<td>2 (6.3%)</td>
<td>3 (9.4%)</td>
<td>5 (15.7%)</td>
<td>0.63</td>
</tr>
<tr>
<td>Dark urine</td>
<td>7 (21.9%)</td>
<td>9 (28.1%)</td>
<td>16 (50.0%)</td>
<td>0.48</td>
</tr>
<tr>
<td>Body aches</td>
<td>8 (25.0%)</td>
<td>5 (15.6%)</td>
<td>13 (40.6%)</td>
<td>0.28</td>
</tr>
<tr>
<td>Grunting</td>
<td>5 (15.6%)</td>
<td>5 (15.6%)</td>
<td>10 (31.2%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Could not sit</td>
<td>5 (15.6%)</td>
<td>7 (21.9%)</td>
<td>12 (37.5%)</td>
<td>0.46</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>2 (6.3%)</td>
<td>1 (3.1%)</td>
<td>3 (9.4%)</td>
<td>0.54</td>
</tr>
<tr>
<td>Cough</td>
<td>8 (25.0%)</td>
<td>10 (31.3%)</td>
<td>18 (56.3%)</td>
<td>0.48</td>
</tr>
<tr>
<td>Jaundice</td>
<td>8 (25.0%)</td>
<td>8 (25.0%)</td>
<td>16 (50.0%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Pallor</td>
<td>15 (46.9%)</td>
<td>16 (50.0%)</td>
<td>31 (96.9%)</td>
<td>0.31</td>
</tr>
<tr>
<td>Respiratory distress</td>
<td>9 (28.1%)</td>
<td>11 (34.4%)</td>
<td>20 (62.8%)</td>
<td>0.47</td>
</tr>
<tr>
<td>Convulsion</td>
<td>10 (31.3%)</td>
<td>13 (40.6%)</td>
<td>23 (71.9%)</td>
<td>0.24</td>
</tr>
<tr>
<td>Coma</td>
<td>2 (6.3%)</td>
<td>3 (9.4%)</td>
<td>5 (15.7%)</td>
<td>0.63</td>
</tr>
<tr>
<td>Liver enlargement</td>
<td>15 (46.9%)</td>
<td>15 (46.9%)</td>
<td>30 (93.8%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Spleen enlargement</td>
<td>14 (43%)</td>
<td>15 (46.9%)</td>
<td>29 (89.9%)</td>
<td>0.54</td>
</tr>
<tr>
<td>Anaemia (pCV &lt;30.0%)</td>
<td>10 (31.3%)</td>
<td>13 (40.6%)</td>
<td>23 (71.9%)</td>
<td>0.24</td>
</tr>
<tr>
<td>Hypoglycemia (glucose&lt; 45mg%)</td>
<td>8 (25.0%)</td>
<td>7 (21.9%)</td>
<td>15 (46.9%)</td>
<td>0.72</td>
</tr>
<tr>
<td>Haemoglobinuria</td>
<td>8 (25%)</td>
<td>8 (25%)</td>
<td>16 (50%)</td>
<td>1.00</td>
</tr>
</tbody>
</table>

Jaundice was observed in 16 patients (50%) at enrolment with 8 patients in each treatment group. By day 3, only 2 and 4 patients had cleared jaundice in quinine and artemether groups respectively. However, by day 7, jaundice had cleared in all the patients in both groups. No patient developed jaundice in the course of treatment. Thirty patients had enlarged liver at day 0 with 15 from each treatment group. At day 3, no patient in quinine group and only one in the artemether group had resolved liver enlargement. However, by day 7, all the patients in artemether and only one in quinine group no longer had enlarged liver. All the remaining 14 patients in the quinine group resolved liver enlargement by day 14.

Of the 29 patients with enlarged spleen, 14 were in quinine group while 15 were in artemether group. By day 7, the spleen enlargement in all the 14 patients in both the quinine and artemether groups had resolved. At day 0, 23 patients (71.9%) had convulsion, with 13 (40.6%) from artemether group and
10 (31.3%) from quinine group. No other patient convulsed in the course of treatment. Five (15.6%) patients presented with coma at day 0 with 2 in quinine and 3 in artemether group. No patient developed coma in the course of treatment. At day 0, 31 of the 32 patients (97%) presented with anorexia. By day 3, only 4 of the 16 (25%) in the artemether group and 7 of the 15 (46.7%) in the quinine group were found to be anorexic. The remaining anorexic patients got better at day 7 for quinine and day 5 for artemether.

No adverse effect of note was observed in the course of treatment with artemether, while 7 (43.8%) patients treated with quinine complained of ringing in the ear and 6 (37.5%) had insomnia.

**DISCUSSION**

We present data on a comparative study on the efficacy and safety of artemether and quinine in the treatment of severe malaria. Patients who were allocated into the two treatment groups had similar presenting features. Vomiting was the commonest gastrointestinal manifestation of severe malaria in children, the reason why this is so are not clearly known, but it has been suggested that it may be due to preferential sequestration of parasites in gastric vascular beds (Sowunmi et al., 2000; Buffet et al., 2011). Cough was observed in 56.3% of the patients and may be due to increased sequestration of parasites in the pulmonary vascular bed or viral respiratory infection. Sequestration, increased parasite biomass and cytoadherence in small vessels by parasitized erythrocytes cause microcirculatory obstruction, reduce vascular lumen thereby reducing blood flow (Dondorp et al., 2000; Simpson et al., 2002). Due to cytoadherence of parasitized erythrocytes. Recently, it was postulated that endothelial protein C receptor is the host receptor responsible for sequestration of infected erythrocytes in the brain and other organs in cerebral malaria (Azasi et al., 2018). Parasite adhesion binds endothelial protein C receptor.

Diarrhoea was the least common of the presenting features in severe malaria as the symptom occurred in only 9.4% of the children. The finding of cough, vomiting and diarrhoea in severe malaria is consistent with previous reports (Anumudu et al., 2004; Sodeinde et al., 1996). Fever as expected was very common as it occurred in 87.5% of the patients. Abdominal organ enlargement was found to be common in this study. Hepatomegaly was found in 93.8% and splenomegaly in 90.6%. It has been suggested that hepatomegaly and splenomegaly may be used as malarialmetric indices (Sowunmi, 1996a). The liver resolution time was faster with artemether than quinine as it took 7 and 14 days respectively. Both drugs resolved enlarged spleen during the course of treatment such that by day 7, all enlarged spleens were resolved in both treatment groups. The spleen is involved in preferential withdrawal of infected erythrocytes from circulation and often undergoes reactive hyperplasia in fulfilling this role (Buffet et al., 2011). This has led to the suggestion that a failure of splenic clearance may be a factor in the development of severe malaria (Bach et al., 2005).

Although the mean malaria parasite density was higher in the artemether treatment group than the quinine group, however, the parasite clearance time of 31.5 hr for artemether was markedly shorter than 46.5 hr for quinine. Artemether has been reported to have a faster malaria clearance time than quinine (Huda et al., 2003). There was no reappearance of malaria parasite after clearance among the patients in both groups except one in whom parasite reappeared by day 7 in artemether group. Recrudescence occurs when artemether is given in short monotherapy. The only patient with recrudescence of malaria parasites had artemether treatment extended by additional five days, which led to full parasite clearance. Coma recovery was faster in the artemether group unlike the finding in Nepal which recorded a faster coma resolution with quinine compared to artemether (Rehman et al., 2013). Fever clearance time of 46.5±20.5 hr with quinine was faster relative to artemether, which was 72.0 ± 27.7 hr.

The fever clearance time with quinine is consistent with the findings of (Huda et al., 2003; Salako et al., 1994). This suggests the anti-inflammatory property of quinine. Similarly, the fever clearance time for artemether in this study is comparable with the finding in Thailand (Karbwang et al., 1995). Artemether, also known as dihydroartemisinin methyl ether is lipid soluble, and may administered as oral, rectal, intramuscular but not intravenous. Artemether may be preferred to artesunate in certain situations of unavailability of artesunate or difficulty with the preparation. Artesunate which is water soluble may be administered as oral, rectal, intramuscular and intravenous at a dose of 2.4 mg/kg. However, the intravenous and intramuscular preparation as well as administration may be challenging, involving patient’s accurate weight and the determination of the number of 60 mg vials required based on the patient’s weight. For parenteral use, artesunate is reconstituted with 1 ml of 5% sodium bicarbonate and must be shaken until the solution is clear, usually takes 2-4 minutes. The reconstituted solution is diluted with normal saline, 2 ml for IM and 5 ml for IV. Dose has to be recalculated to ascertain the required dose to be withdrawn for the predetermined route of administration (Malaria Action Program for States, 2013). Any left-over reconstituted injection has to be discarded because the drug will recrystallize within 1 hour and will be unsuitable for administration due to the potential of crystallization within the vessels and possible gangrene.

Jaundice clearance was better with artemether than quinine, as by day 3, 50% of jaundiced patients were clinically cleared in artemether as against 25% in quinine treatment group. By day 7, all the patients with jaundice were clinically cleared. The jaundice in malaria has been reported to have haemolytic, hepatic and cholesterol component (Molyneux et al., 1989). The fact that quinine is known to cause haemolysis may perhaps be responsible for its slower jaundice clearance. Proteinuria and haemoglobinuria occurred in 50% of the patients at presentation. This is similar to 20-50% and 44.4% reported from early studies in children with *Plasmodium falciparum* malaria at enrolment (Sowunmi, 1996b). Proteinuria is a common feature of febrile illnesses, while haemoglobinuria is usually due to massive erythrocyte destruction in severe malaria cases. Both proteinuria and haemoglobinuria got cleared in the course of treatment by both drugs. There was no evidence of adverse local, gastrointestinal, cardiovascular, and neurological or other systemic toxic effect. The adverse reaction observed with quinine such as tinnitus and insomnia were mild and disappeared on stoppage of treatment. This is in consonance with earlier reported observation (White et al., 1982). In the treatment of severe malaria, parenteral artesunate or artemether for a minimum of 24 hours or when patient recovers from coma and...
can tolerate orally should be followed by a course of artesinin combination therapy (ACT).

In conclusion, the study has demonstrated that quinine and artemether are effective and safe in the treatment of severe malaria. Quinine however has a shorter fever clearance time than artemether, which may be attributed to the antipyretic properties of quinine. However, artemether relative to quinine has (i) better tolerance and safety (ii) more rapid malaria parasite clearance time and coma recovery time (iii) a faster jaundice resolution time and (iv) better liver enlargement resolution time.

REFERENCES


